Drug Delivery Systems for the Combination Therapy of Cancer and Chronic Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (20 January 2024) | Viewed by 363
Special Issue Editors
Interests: blood–brain penetrating nanoparticles for brain cancer and CNS diseases and drug delivery technologies for enhancing cancer therapies and modulating tumor microenvironments
Special Issue Information
Dear Colleagues,
Combination therapy has shown increased significance in clinical practice for many diseases, including cancer, due to its promise in providing superior therapeutic and diagnostic benefits. The use of specific modalities can include chemo-drug combinations, theranostics or other forms of combined therapy (e.g., immunotherapy). To achieve synergistic or additive outcomes of combination therapy, drug delivery systems that coordinate the release and accumulation of therapeutical agents are critical. This Special Issue aims to highlight and capture the recent progress and contemporary landscape of drug delivery systems in various dosage forms for combination therapy, including, but not limited to, micro- and nanoparticles, hydrogels and hybrid systems to mitigate the disease burden and minimize unwanted adverse effects.
We are pleased to invite you to submit articles on all aspects of “Drug Delivery Systems Based on Combination Therapy of Cancer and Chronic Diseases”. Original research articles, communications, and reviews are welcome. Research areas may include (but not limited to) the following: delivery technologies, therapeutic evaluations, and characterization (e.g., drug release and excipient selection) of drug combinations for small molecules, radiotracers, photosensitizers, proteins, and genes, as well as drug delivery system-assisted treatment schedules for patients with cancer and chronic diseases (e.g., Alzheimer’s disease and eye diseases).
We look forward to receiving your contributions!
Prof. Dr. Shirley X. Y. Wu
Dr. Ruixue Zhang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- formulation
- nanotechnology
- biotechnology
- cancer therapy
- drug combination
- theranostics
- biological barrier
- drug release
- drug bioavailability
- drug excipient interaction
